SK Bioscience stock (KR7302440009): Sanofi expands pneumococcal vaccine partnership

SK Bioscience Co Ltd, a leading South Korean vaccine developer, announced an expanded partnership with Sanofi in December 2024 to jointly develop and commercialize next-generation pneumococcal vaccines. This builds on their prior agreement and targets innovative conjugate vaccines to address evolving bacterial strains, according to openPR as of December 2024. The deal underscores SK Bioscience's strengthening position in the global vaccine market, with potential implications for US investors tracking biotech exposure to Asia.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

SK Bioscience: core business model

SK Bioscience focuses on research, development, and manufacturing of vaccines for infectious diseases. Incorporated as part of the SK Group, the company leverages advanced platform technologies like its USD100 technology for subunit vaccines and CRM-based conjugation for polysaccharide vaccines. Its portfolio includes COVID-19 vaccines such as SkyCovione, approved in South Korea and under review elsewhere, as detailed on the company IR site as of 2026.

The business model emphasizes partnerships with global pharma giants, contract development and manufacturing (CDMO), and government contracts, particularly in Asia. This approach has enabled rapid scaling, with production capacity exceeding 20 million doses annually for certain vaccines.

Main revenue and product drivers for SK Bioscience

Key products include pneumococcal conjugate vaccines (PCV), influenza vaccines, and COVID-19 shots. The Sanofi collaboration, expanded in December 2024, targets a 20-valent PCV to combat antimicrobial resistance, a growing concern in the US market per CDC data. Revenue from vaccine sales and royalties forms the bulk, supplemented by CDMO services.

In Q1 2026, peer SK Innovation reported strong revenue growth, indicating sector momentum that benefits vaccine developers like SK Bioscience through shared supply chains, though specific figures for SK Bioscience require latest IR updates.

Industry trends and competitive position

The global vaccine market, valued at over $60 billion in 2024 per Statista data published in 2025, is driven by post-pandemic demand and next-gen vaccines. SK Bioscience competes with Pfizer, GSK, and Merck but differentiates via cost-effective Asian manufacturing and tech platforms. US investors note its exposure to mRNA alternatives and combination vaccines amid regulatory shifts.

Why SK Bioscience matters for US investors

Listed on KOSDAQ, SK Bioscience offers US investors indirect exposure to Asia's biotech boom via ADRs or funds. Its Sanofi tie-up provides pipeline access to Western markets, relevant as US pneumococcal cases rise, with CDC reporting 30,000 annual deaths linked to infections as of 2025 data.

Conclusion

The expanded Sanofi partnership positions SK Bioscience for potential growth in pneumococcal vaccines, amid a robust pipeline and strategic alliances. While market volatility persists in biotech, the company's tech platforms and Asian manufacturing edge offer diversified exposure. US investors may track upcoming clinical milestones for further developments.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.